Effects of radium-223 dichloride (Ra-223) on total alkaline phosphatase (ALP) and prostate-specific antigen (PSA) in patients with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases from the phase 3 ALSYMPCA trial

被引：0
|
作者：
Strauss, A. [1 ]
Heinrich, D. [2 ]
Parker, C. [3 ,4 ]
Shan, M. [5 ]
Wilhelm, S. [5 ]
Garcia-Vargas, J. [5 ]
O'Bryan-Tear, C. G. [6 ]
Sartor, O. [7 ]
机构：
[1] Univ Med Gottingen, Urol Klin, Gottingen, Germany
[2] Akershus Univ Hosp, Lorenskog, Norway
[3] Royal Marsden NHS Fdn Trust, Sutton, Surrey, England
[4] Inst Canc Res, Sutton, Surrey, England
[5] Bayer Healthcare, Whippany, NJ USA
[6] Algeta ASA, Oslo, Norway
[7] Tulane Univ, Ctr Canc, New Orleans, LA 70118 USA
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2014年 / 37卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
V553
引用
收藏
页码：177 / 178
页数：2
相关论文
共 50 条
  • [41] Effect of radium-223 dichloride (Ra-223) on hospitalisation: An analysis from the phase 3 randomised Alpharadin in Symptomatic Prostate Cancer Patients (ALSYMPCA) trial
    Parker, Christopher
    Zhan, Lin
    Cislo, Paul
    Reuning-Scherer, Jonathan
    Vogelzang, Nicholas J.
    Nilsson, Sten
    Sartor, Oliver
    O'Sullivan, Joe M.
    Coleman, Robert E.
    EUROPEAN JOURNAL OF CANCER, 2017, 71 : 1 - 6
  • [42] 1.5-year post-treatment follow-up of radium-223 dichloride (Ra-223) safety in patients with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases from the phase 3 ALSYMPCA study.
    Parker, Chris
    Vogelzang, Nicholas J.
    Sartor, A. Oliver
    Bottomley, David
    Coleman, Robert E.
    Skjorestad, Irene
    Wahba, Mona
    Nilsson, Sten
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [43] Hematotoxicityand non-hematological adverse events of Ra-223 dichloride (Ra-223) in patients with castration-resistant prostate cancer (CRPC) and bone metastases
    Ahmadzadehfar, H.
    Azgomi, K.
    Rogenhofer, S.
    Bundschuh, R.
    Kuerpig, S.
    Thomas, L.
    Essler, M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2015, 42 : S738 - S739
  • [44] 1.5-YEAR POSTTREATMENT FOLLOW-UP OF RADIUM-223 DICHLORIDE (RA-223) SAFETY IN PATIENTS (PTS) WITH CASTRATION-RESISTANT PROSTATE CANCER (CRPC) AND SYMPTOMATIC BONE METASTASES FROM ALSYMPCA: CHARACTERIZATION OF HEMATOLOGIC SAFETY PROFILES
    Parker, C.
    Vogelzang, N.
    Sartor, O.
    Bottomley, D.
    Coleman, R. E.
    Skjorestad, I.
    Aksnes, A.
    Wahba, M.
    Nilsson, S.
    ANNALS OF ONCOLOGY, 2014, 25
  • [45] ESTIMATING THE ECONOMIC IMPACT OF RADIUM RA 223 DICHLORIDE (RADIUM-223) IN TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER (CRPC) WITH SYMPTOMATIC BONE METASTASES AND NO KNOWN VISCERAL METASTATIC DISEASE
    Valderrama, A.
    Bilir, S. P.
    Wehler, E. A.
    Seal, B. S.
    Wen, L.
    Yaldo, A.
    Munakata, J.
    VALUE IN HEALTH, 2014, 17 (03) : A74 - A74
  • [46] Radium-223 Dichloride (Ra-223) Impact on Skeletal-Related Events, External Beam Radiation Therapy (EBRT), and Pain in Patients With Castration-Resistant Prostate Cancer (CRPC) With Bone Metastases: Updated Results From the Phase 3 ALSYMPCA Trial
    Michalski, J.
    Sartor, O.
    Parker, C.
    Shan, M.
    Garcia-Vargas, J.
    Aksnes, A.
    Vogelzang, N. J.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2013, 87 (02): : S108 - S109
  • [47] Radium-223 Dichloride: A Novel Treatment Option for Castration-Resistant Prostate Cancer Patients With Symptomatic Bone Metastases
    McGann, Shane
    Horton, Evan R.
    ANNALS OF PHARMACOTHERAPY, 2015, 49 (04) : 469 - 476
  • [48] Radium-223 Dichloride: A Review of Its Use in Patients with Castration-Resistant Prostate Cancer with Symptomatic Bone Metastases
    Matt Shirley
    Paul L. McCormack
    Drugs, 2014, 74 : 579 - 586
  • [49] Radium-223 Dichloride: A Review of Its Use in Patients with Castration-Resistant Prostate Cancer with Symptomatic Bone Metastases
    Shirley, Matt
    McCormack, Paul L.
    DRUGS, 2014, 74 (05) : 579 - 586
  • [50] Radium-223 dichloride in castration-resistant prostate cancer with symptomatic bone metastases: a guide to its use
    Shirley M.
    McCormack P.L.
    Drugs & Therapy Perspectives, 2016, 32 (3) : 98 - 103
12345